The association between BMI and continuity of etonogestrel (ENG)-releasing implant.

Aya Mohr SassonLeanne DalalAsha Bhalwal

Published in: International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics (2024)

Continuation of etonogestrel-releasing implant contraception treatment was associated with the presence of side effects that were more often reported in non-obese women. BMI was not found to be a significant factor influencing adherence to treatment.

Keyphrases

body mass index
adipose tissue
type diabetes
polycystic ovary syndrome
soft tissue
pregnant women
physical activity
weight gain
bariatric surgery
skeletal muscle
smoking cessation